KR20160094505A - Composition for inhibition of xanthine oxidase containing hydrolysates of abalone - Google Patents

Abstract

The present invention relates to a composition for inhibition of xanthine oxidase, containing a hydrolysate of abalone as an effective component. The hydrolysate of abalone, more specifically, a hydrolysate of abalone internal organs obtained by hydrolysis with at least one hydrolase selected from a group consisting of alcalase and neutrase is effective in inhibiting xanthine oxidase, and can be used as an effective component of a food composition for mitigating or preventing hyperuricemia-induced diseases, or as the effective component of a curative or preventive medical composition. Moreover, the hydrolysate of abalone does not cause side effects since the hydrolysate is acquired from a natural substance, thus takes a great industrial significance.

Description

TECHNICAL FIELD The present invention relates to a composition for inhibiting xanthine oxidase comprising an upturned hydrolyzate as an active ingredient. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for inhibiting xanthine oxidase,

The present invention relates to a composition for inhibiting xanthine oxidase comprising a hydrolyzate of a natural product as an active ingredient, and more particularly to a composition for treating, improving or preventing a disease caused by hyperuricemia.

Abalone is a mollusc, belonging to the abalone family, and refers to a shellfish belonging to abalone, which mainly lives in an island region or reef of 5 to 50 m in depth in the liver. It is one of the major aquatic products that has been used as food for a long time. It is also used as a raw material for canned foods, canned foods, canned foods or canned foods.

The abalone is a high protein and has a total calories per 100 g of 100 cal. It contains various minerals and vitamins, and is recognized as an expensive food due to its unique taste and texture.

The abalone that is mainly cultivated in Korea is produced as abalone, black abalone and horse abalone. Since the 1960s, efforts have been made by the National Fisheries Research and Development Agency to produce seeds. . The abalone production of Korea has been produced in the Chonnam region since 1970, and it has been produced in the scale of 100 to 200 tons until the 1990s. However, since the marine caged aquaculture has been spreading since the 2000s, , And it has increased to about 1,000 tons. As this increase continues, domestic abalone production has rapidly expanded to 8,819 tons in 2012.

However, along with this quantitative expansion, shipments of large size abalone, which was recently recognized as a luxury aquatic product, dropped to 2% in 2012, while shipments of small-sized abalone, which is relatively low in price, From 8% in 2007 to 40% in 2012, and this trend has led to a decline in the profitability of the abalone industry.

As an alternative to overcome this problem, we are exporting bowls and processed abalones to Japan and China. As of 2012, export volume is reported to be 1,333 tons. In addition, various attempts have been made to utilize the overturned garbage, which corresponds to the waste generated in the processing of overturning, in relation to the processing overturn, which accounts for a considerable amount of exports.

On the other hand, along with rapid economic development, disease patterns are greatly changed. Therefore, metabolic diseases such as diabetes, obesity, gout, and circulatory diseases such as stroke, ischemic heart disease and cerebrovascular disease are becoming more important.

According to the data released by the National Statistical Office, the proportion of elderly people aged 65 or older accounted for 9.1% of the total population in 2005, and the share of the under-14 age group is gradually decreasing. And 7.2%, respectively, indicating that our society has already entered an aging society. Also, as of 2003, the average age of Koreans is 77.5, and the elderly population is rapidly increasing. Meanwhile, GNI per capita GNI announced by the National Statistical Office was $ 14,162 in 2004, which is increasing by more than 10% each year. This increase in profits leads to an increase in the interest in individual quality of life and a desire for a healthy aging life.

Due to these changes in social conditions, the number of deaths due to communicable diseases, which is the main cause of death in the past, is sharply decreasing, while the number of deaths due to metabolic or degenerative diseases is steadily increasing, and the number of deaths due to metabolic or degenerative diseases The number of patients experiencing difficulties is also increasing.

Hyperuricemia is a metabolic disorder caused by excessive accumulation of uric acid in the purine metabolic system, which is a kind of nucleic acid base. This hyperuricemia causes various metabolic diseases such as hyperuricemia Disease is induced.

Specifically, uric acid is the final metabolite of purine, which is produced from xanthine by xanthine oxidase (XO) in the body. It is known that xanthine oxidase is greatly activated in a pathological state such as body stress.

In addition, 90% of the hyperuricemia is caused by insufficient excretion of the kidney, and about 10% is caused by excessive production of uric acid. Inadequate excretion of uric acid occurs in the urinary tract of the kidneys, whereas excessive uric acid production is produced by excess of dietary purine intake or increased activity of xanthine oxidase.

Diseases caused by hyperuricemia include gout, back pain, hyperuricemia, or urinary diuresis. A typical disease among these diseases is gout which causes arthritis and the like.

The gout is a disease that causes inflammation and pain by accumulating crystals of uric acid in the joint region due to hyperuricosis, and complication is uric acid stone disease, diabetes, obesity, hypertension, arteriosclerosis or nodosis.

It is known that the ventilation does not have any subjective symptoms at first, but when it progresses gradually, degeneration of the human tissue occurs and severe subjective symptoms appear. Specifically, in the initial stage of the onset of the disease, the joints of the limbs have severe pain at night and symptoms such as breaking the bed are appeared, and the symptoms become worse due to the continuing pain.

In the case of diseases caused by hyperuricemia, including such gout, therapies have been developed to inhibit the production of uric acid, along with therapies related to urinary excretion in the kidneys.

Currently, the gynecological medicines that are currently on the market are very limited, mainly colchicine and nonsteroidal analgesic drugs and glucocorticoid hormones, and they exhibit anti-inflammatory analgesic effects, but they do not have the role of lowering uric acid, , Side effects of gastrointestinal bleeding symptoms are problematic.

Recently, many anticholinergic agents (alopuridol), which plays an important role in the production of uric acid, have been developed along with anti-hypertension agents such as progesterone and serpin pyrazone. However, most of the xanthine oxidase inhibitors that have been developed so far are compound-derived drugs that are easily decomposed in the pharmaceutical dosage form, that is, they are not stable but also act on other cells to inhibit digestive disorders, bone marrow production inhibition, kidney disorders, And the like.

In order to solve such a problem, it is urgently required to develop a natural substance-derived xanthine oxidase inhibitor which is safe without adverse side effects. Particularly, in the case of a xanthine oxidase inhibitor derived from a natural product used as a food, it is easy to secure safety, and thus there is a growing need for research.

KR 10-1018403 B KR 10-0759467 B KR 10-0492470 B KR 2014-0040611 A

In order to meet such a demand, the present invention relates to a pharmaceutical composition for effectively inhibiting xanthine oxidase, inhibiting the production of uric acid, and being useful for the treatment, prevention or amelioration of hyperuricosidic disease, It is an object of the present invention to provide a composition which is not problematic and is excellent in safety.

In order to achieve the above object, the present invention provides an abalone hydrolyzate which not only effectively inhibits xanthine oxidase but also has no side effects caused by natural products, and is excellent in safety.

More particularly, the present invention relates to a composition for inhibiting xanthine oxidase, which contains, as an active ingredient, an overturned hydrolyzate hydrolyzed using at least one hydrolase selected from the group consisting of Alcalase and Neutrase to provide.

The overturned hydrolyzate may be obtained by treating both the alchemical and the natraceuticals, and the mixing throughput may preferably be 6: 1 (Alcalase: Nutraceutical).

In addition, the overturned hydrolyzate may be one obtained by treating Alkarase and Nutra sequentially with Alcalase and then treating with Neutrase to hydrolyze the Abalone internally hydrolyzate, In sequential treatments, the throughput of the alcalase and the neutrase may preferably be 6: 1 (Alkalase: Nutraceutical).

The overturned hydrolyzate may be obtained by hydrolyzing the inverted embryo with at least one hydrolase selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours.

The composition for inhibiting xanthine oxidase can inhibit the production of uric acid, thereby exerting therapeutic, improving or preventive effects against diseases caused by hyperuricemia.

In view of the above, the present invention provides a method for treating a disease caused by hyperuricemia comprising an invertase hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase as an active ingredient Or a food composition for improving or preventing osteoporosis.

The food composition may be a functional food.

The hyperuricemia-induced disease may be any one selected from the group consisting of gout, low back pain, hyperacidemia, and uricosuria, preferably gout.

The overturned hydrolyzate may be obtained by treating both the alchemical and the natraceuticals, and the mixing throughput may preferably be 6: 1 (Alcalase: Nutraceutical).

In addition, the overturned hydrolyzate may be one obtained by treating Alkarase and Nutra sequentially with Alcalase and then treating with Neutrase to hydrolyze the Abalone internally hydrolyzate, In sequential treatments, the throughput of the alcalase and the neutrase may preferably be 6: 1 (Alkalase: Nutraceutical).

The overturned hydrolyzate may be obtained by hydrolyzing the inverted embryo with at least one hydrolase selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours.

In another aspect, the present invention relates to a method for treating a disease caused by hyperuricemia comprising an invertible hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase, Or a pharmaceutical composition for treatment or prevention.

The hyperuricemia-induced disease may be any one selected from the group consisting of gout, low back pain, hyperacidemia, and uricosuria, preferably gout.

The overturned hydrolyzate may be obtained by treating both the alchemical and the natraceuticals, and the mixing throughput may preferably be 6: 1 (Alcalase: Nutraceutical).

In addition, the overturned hydrolyzate may be one obtained by treating Alkarase and Nutra sequentially with Alcalase and then treating with Neutrase to hydrolyze the Abalone internally hydrolyzate, In sequential treatments, the throughput of the alcalase and the neutrase may preferably be 6: 1 (Alkalase: Nutraceutical).

The overturned hydrolyzate may be obtained by hydrolyzing the inverted embryo with at least one hydrolase selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours.

In another aspect, the present invention relates to a method for producing an overturned hydrolyzate by reacting at least one hydrolytic enzyme selected from the group consisting of Alcalase and Neutrase, The present invention provides a method for producing an abalone enzyme hydrolyzate having an ability to inhibit xanthine oxidase.

As used herein, the term " prophylactic " means any action that inhibits the symptoms of a particular disease, including gout, or delays its progress, by administration of the composition of the present invention.

As used herein, the term treatment refers to any improvement action that improves or alleviates the symptoms of a particular disease, including gout, by administration of the composition of the present invention.

As used herein, the term refers to all animals such as humans, monkeys, dogs, goats, pigs or rats having a disease in which the symptoms of a specific disease including gout are treated by administration of the composition of the present invention.

Administration of the terms as used herein means providing the subject invention with a composition of the invention in any suitable manner.

As used herein, the term pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit or risk ratio applicable to medical treatment, including the type of disease, severity, activity of the drug, The drug's sensitivity, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including simultaneously used drugs, and other factors well known in the medical arts.

The inventors of the present invention focused on the fact that, in the case of natural products used as food, the safety related to side effects or resistance is less likely to be a problem than that of chemically synthesized drugs. Thus, the present inventors have found that a composition derived from a natural product, , It was confirmed that the abalone hydrolysates inhibited the production of uric acid by inhibiting the activity of xanthine oxidase and found that the treatment, improvement or prevention effect on gout induced diseases such as gout was excellent , And that the composition containing the same as an active ingredient can treat, prevent or ameliorate diseases caused by hyperuricemia, including gout, to complete the present invention.

Hereinafter, the present invention will be described in more detail.

The present invention relates to a composition for inhibiting xanthine oxidase comprising, as an active ingredient, an overturned hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase .

In the present invention, the pacific saury (Coloabis saira) is a mollusc, belonging to the genus Liliaceae, and is called Pufferfish, Prunus myrtle or Forbidden City. Abalone is abundant in the islands and reefs of 5 to 50 m depth in the liver of Kannon, and it is algae such as kelp, rhubarb, seaweed, do.

The abalone is large, oval with a length of more than 10cm, and the layer of stratum, which is wrapped in a spiral shape, is small and sloped backward. Most of it is the largest layer of stratum There are holes on top of it. These holes are blocked except for a few backs, and the open hole is the outflow hole, and the excreta is also sent here. The underside of the shell is large open and has a strong pearl luster.

The delicacy of the abalone is wrapped in a shell, attached to the shell by the shell muscle, and the trunk protrusion is developed around it. The foot is large and wide. There is a pair of tactile eyes and eyes on the head, And the symmetry of the heart is one pair.

The abalone is a morphological variant and the external genitalia are not developed. It is fertilized by late-autumn to early winter as a livelihood. It is male that the germ line is yellowish white and male is green.

Abalone, which has been used for food for a long time, is an expensive food material, eaten by eating or processing the circuit, succeeded in culturing in Korea and is becoming a major source of farm food in Chonnam region such as Wando. Haliotis 　 discus 6 species such as hannai and turbulent Haliotis discus , H. gigantea or H. diversicolor diversicolor are mainly cultured and cultured.

In the present invention, the hydrolyzate refers to a substance produced after protein degradation. The protein is also referred to as a seafood product, and the abalone hydrolyzate means a substance in which the abalone protein is hydrolyzed by a protein hydrolyzing enzyme, Means a substance whose protein is produced by hydrolysis by a protein hydrolyzing enzyme. The protein hydrolyzing enzyme includes an enzyme that performs a chemical reaction that hydrolyzes a peptide bond or the like in a protein molecule to convert the protein into an amino acid or a peptide mixture.

The overturned hydrolyzate of the present invention may be one prepared by a conventional method for producing hydrolysates of fish and shellfish, and preferably one prepared by hydrolysis using enzymes. More preferably, the protein hydrolyzing enzyme is added to the abalone after the overturning and removing of the shell of the present invention, and after the reaction is completed, the enzyme is inactivated and the hydrolyzate obtained by removing the insoluble material is lyophilized have.

The protein hydrolyzing enzyme may be at least one selected from the group consisting of an alkarase and a neutra, preferably an alkarase or an alkarase and a neutra, more preferably an alkarase and a nitro .

The alkaline enzyme may be, for example, 0.1 AU to 10 AU, or 0.5 AU to 5 AU, or 1 AU to 3 AU per 180 g of the appendage, based on the enzyme unit or enzyme activity unit (AU) AU can be added.

The Nutraceutical enzyme may be, for example, 0.1 AU to 1 AU, or 0.2 AU to 0.8 AU, or 0.4 AU to 0.5 AU per 180 g of the appendage organ, based on the enzyme unit or enzyme activity unit (AU) Can be added.

The reaction conditions of the protein hydrolyzing enzyme can be carried out under optimal reaction conditions of each enzyme according to the kind of the enzyme, and the reaction time is 30 minutes to 24 hours, preferably 1 hour to 12 hours, 5 hours.

The inactivation of the enzyme may be carried out by a conventional method appropriately selected depending on the type of enzyme and is carried out at a temperature of 80 to 100 DEG C, preferably 85 to 95 DEG C, more preferably 87 to 92 DEG C for 5 minutes To 1 hour, preferably from 7 minutes to 30 minutes, and more preferably from 12 minutes to 17 minutes.

The obtained overturned hydrolyzate can be stored or dried by using a deep freezer. In addition, the overturned hydrolyzate can be obtained by completely removing moisture through concentration and lyophilization of the obtained hydrolyzate.

The overturned hydrolyzate may preferably be one obtained by treating alkaline and Nutra sequentially with Alcalase, then treating with Neutrase and hydrolyzing, The treatment time of the enzyme may be 2 to 6 hours, preferably 2 to 30 minutes to 4 hours, more preferably 2 hours to 45 minutes to 3 hours and 30 minutes. In the sequential treatment, the throughput of the alkalase and the Ntrease may be preferably 6: 1 (Alkalase: Nutraceutical) based on the enzyme unit or the unit of enzyme activity (AU).

The enzyme unit is defined as the amount of the enzyme, which is defined as the amount of the enzyme that is converted into a product by a certain amount of enzyme per unit time. Generally, the amount of enzyme capable of changing 1 μmol of substrate per minute .

The overturned hydrolyzate may have a size of 10 kDa or less, preferably 10 Da to 10,000 Da, based on the molecular weight.

The overturned hydrolyzate hydrolyzed by using one or more hydrolytic enzymes selected from the group consisting of Alcalase and Neutrase, which are active ingredients of the composition for inhibiting xanthine oxidase, inhibits the production of uric acid , It is possible to exert treatment, improvement or prevention effect on diseases derived from hyperuric acidosis, and it is manufactured using natural substances that can be used for edible purposes, so that there is no problem of side effects and safety is excellent. The visceral hydrolyzate can be utilized as an active ingredient of a food composition or a pharmaceutical composition for the treatment, improvement or prevention of diseases derived from hyperuricemia.

In this respect, the present invention relates to a method for the treatment and prophylaxis of diseases caused by hyperuricemia comprising an invertible hydrolyzate hydrolyzed by using at least one hydrolytic enzyme selected from the group consisting of Alcalase and Neutrase, Or a pharmaceutical composition for treatment or prevention.

The hyperuricemia-induced disease may be any one selected from the group consisting of gout, low back pain, hyperacidemia, and uricosuria, preferably gout.

Hyperuricemia refers to a state in which the concentration of uric acid in the blood is increased, specifically, a state in which the concentration of monosodium urate exceeds the limited solubility limit in the serum. In most epidemiological studies, the upper limit of men is 7.0 mg / dl, and the female is 6.0 mg / dl. Therefore, the actual upper limit of hyperlipidemia is defined as 7.0 mg / dl or more, and the uric acid saturation Is about 7 mg / dl. Generally, when the concentration exceeds this concentration, it becomes physico-chemical supersaturated state and corresponds to hyperuricemia.

The ventilation (Gout) refers to various disease groups found only in humans, and refers to an arthritic disease caused by an increase in the concentration of tissue and blood uric acid. The above-mentioned gout is a disease that occurs more and more with age, and it is called a disease king or a disease of a king, accompanied by a great pain due to inflammatory reaction caused by uric acid crystals in the big toe region as a main symptom.

In general, symptoms associated with gout include hyperuricemia of serum uric acid, recurrence of acute arthritis, presence of monosodium urate crystals in the synovial fluid leukocyte, Of monosodium urate crystals and associated deformities and deformities of the joints, and it is reported that the symptoms associated with kidney disease are mainly seen.

The overturned hydrolyzate may be obtained by treating both the overturned embers with both of an alkaline and a nutrient. The mixing throughput is preferably 6: 1 based on the enzyme unit or enzyme activity unit (alkalase: ).

In addition, the overturned hydrolyzate may be one obtained by treating Alkarase and Nutra sequentially with Alcalase and then treating with Neutrase to hydrolyze the Abalone internally hydrolyzate, In the sequential treatment, the throughput of the alkalase and the Ntrease may preferably be 6: 1 (alkalazine: Nutraceutical) based on the enzyme activity unit.

The overturned hydrolyzate may be obtained by hydrolyzing the inverted embryo with at least one hydrolase selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours.

Since the overturned hydrolyzate effectively inhibits xanthine oxidase, it has an effect of treating, preventing or improving diseases caused by hyperuricosis including gout.

The composition for treating or preventing a disease caused by hyperuricosidia, including gout containing the above-mentioned abalone hydrolyzate as an active ingredient, can be directly applied to animals including humans. The animal is a group of organisms corresponding to plants. It mainly consumes organic matter as nutrients, and digestion, embryogenesis and respiratory organs are differentiated. Preferably, it is a mammal, more preferably a human.

The composition for treating or preventing diseases caused by hyperuricosis including gout containing the overturned hydrolyzate of the present invention as an active ingredient may contain the overturned hydrolyzate alone and may be used alone or in combination with other medicines A pharmaceutically acceptable carrier, excipient or diluent.

When the composition for treating or preventing diseases caused by hyperuric acid including gout containing the overturned hydrolyzate as an active ingredient is provided as a mixture with other ingredients besides the overturned hydrolyzate as an effective ingredient, 0.001% to 99.9% by weight, preferably 0.1% by weight to 99% by weight, more preferably 0.1% to 99% by weight, of the overturned hydrolyzate, based on the total weight of the composition for treating or preventing diseases caused by hyperuricosuria, May comprise from 1% to 50% by weight.

When a composition for treating or preventing a disease caused by hyperuricosis including gout comprising the above-mentioned abalone hydrolyzate as an active ingredient is used as a medicament, the administration method may be either oral or parenteral, and examples thereof include oral, transdermal, subcutaneous, It can be administered via various routes including veins or muscles.

In addition, the formulations of the compositions may vary depending on the method of use and may be formulated employing methods known in the art to which the present invention pertains so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal .

In general, solid dosage forms for oral administration include tablets, pills, soft or hard capsules, pills, powders and granules, which may contain one or more Excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, liquids, LIMONADES, EMULSIONS and SYRUPS. In addition to water and liquid paraffin, which are commonly used simple diluents, Excipients such as wetting agents, sweetening agents, perfumes, preservatives, and the like.

Forms for parenteral administration may also include creams, looses, ONITMENTS, ointments, PLASTERS, LIQUIDS AND SOURTIONS, AEROSOLS, Or may be in the form of FRUIDEXTRACTS, ELIXIR, INFUSIONS, SACHET, LINIMENTS, PATCH or INJECTIONS.

Furthermore, the compositions of the present invention may be formulated using any suitable method known in the art or using methods disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA .

The pharmaceutically acceptable carrier, excipient or diluent may be selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acicia gum, alginate, gelatin, calcium But are not limited to, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, calcium carbonate, calcium phosphate, calcium phosphate, calcium phosphate, phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, Propylene glycol, liquid paraffin, and physiological saline. However, it is not limited thereto, and any conventional carrier, excipient or diluent may be used.

When a composition for treating or preventing diseases caused by hyperuricemia including gout containing the above-mentioned inversion-type hydrolyzate as an active ingredient is weakly formulated, it is possible to use conventional fillers, extenders, binders, disintegrators, surfactants, anticoagulants, A wetting agent, a flavoring agent, an emulsifying agent, or an antiseptic, and may be used either orally or parenterally. Preferably, it may be used for oral administration. Particularly, solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like. These solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose, (sucrose), lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to commonly used diluents such as water and liquid paraffin, various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like .

The dose of the composition for treating or preventing a disease caused by hyperuricosis including gout comprising the above-described abalone hydrolyzate according to the present invention as an active ingredient can be determined depending on the administration method, the age, sex and weight of the recipient, And can be appropriately selected by those skilled in the art. For example, a composition for treating or preventing a disease caused by hyperuricacidosis including gout comprising the above-mentioned abalone-decomposable hydrolyzate of the present invention as an active ingredient may be used in an amount of 0.0001 (body weight) to 1000 mg / kg (body weight), and more preferably 0.01 mg / kg (body weight) to 100 mg / kg (body weight). The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the composition for treating or preventing diseases caused by hyperuricosis including gout containing the overturned hydrolyzate of the present invention as an active ingredient can be used not only for the hydrolysates of abalone but also for the inhibition of known xanthine oxidase, , An extract, a hydrolyzate or a peptide having a preventive or ameliorative effect, and may be contained in an amount of 5 to 20 parts by weight per 100 parts by weight of the abalone hydrolyzate.

The present invention also relates to a food composition for improving or preventing diseases caused by hyperuricemia, including gout comprising an overturned hydrolyzate as an active ingredient. Examples of the food composition of the present invention include a food, a food additive, a beverage or a beverage additive, and preferably a functional food.

Specifically, the food composition for improving or preventing the disease caused by hyperuricosuria comprises at least one hydrolyzate selected from the group consisting of Alcalase and Neutrase, Or a food composition for improving or preventing a disease caused by hyperuricemia.

The hyperuricemia-induced disease may be any one selected from the group consisting of gout, low back pain, hyperacidemia, and uricosuria, preferably gout.

The overturned hydrolyzate may be obtained by treating both the overturned embers with both of an alkaline and a nutraceutical agent, and the mixing throughput is preferably 6: 1 (alkalazine: Nutraceutical) based on enzyme activity units have.

In addition, the overturned hydrolyzate may be one obtained by treating Alkarase and Nutra sequentially with Alcalase and then treating with Neutrase to hydrolyze the Abalone internally hydrolyzate, In the sequential treatment, the throughput of the alkalase and the Ntrease may preferably be 6: 1 (alkalazine: Nutraceutical) based on the enzyme activity unit.

In addition, the overturned hydrolyzate may be one obtained by hydrolyzing the inverted embryo with at least one hydrolase selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours.

The food composition for improving or preventing diseases caused by hyperuricosidic acid, which contains the above-described abalone hydrolyzate as an active ingredient, may further comprise suitable carriers, excipients and diluents conventionally used in the production thereof.

As used herein, the term " food " means a natural product or a processed product containing one or more nutrients. Preferably, it means that the food can be directly eaten through a certain degree of processing. It is intended to include food, food additives, health functional foods and beverages.

Examples of the foods that can contain the overturned hydrolyzate as an active ingredient of the food composition of the present invention include various foods, beverages, gums, tea, vitamin complex, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The food, beverage or food additive may be prepared by a conventional production method.

In the present invention, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques and the like, the regulation of the biological defense rhythm of the food composition, Refers to a food which is processed and designed so as to sufficiently exhibit a body control function related to the body, such as suppression of xanthine oxidase, uric acid production or blood uric acid reduction. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In the present invention, beverage is a generic term for drinking or enjoying a taste, and is intended to include functional beverages. The beverage is not particularly limited as long as it contains the overturned hydrolyzate as an active ingredient as an essential ingredient at the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient have. Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and Xylitol, sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention can be used for natural fruit juice, fruit juice drink, Of the pulp of the present invention.

In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and aggravating agents (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. These components can be used independently or in combination. The additive may be added in an amount of 0 to 20 parts by weight, preferably 0.00001 to 15 parts by weight, per 100 parts by weight of the overturned hydrolyzate of the present invention, but is not limited thereto.

The functional beverage according to the present invention can be used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage acts on the specific purpose by physical, biochemical or biotechnological techniques, Means a beverage which has been designed so that the body control function related to restoration and the like is sufficiently expressed in the living body.

The functional beverage is not particularly limited to the ingredients other than the above-mentioned invertible hydrolyzate which is the active ingredient of the present invention as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates as an additional ingredient ≪ / RTI > Examples of such natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and xylitol , Sorbitol, and erythritol. Natural flavors (tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The natural carbohydrate may be included in an amount of 0 to 20 parts by weight, preferably 1 to 18 parts by weight, more preferably 5 to 12 parts by weight per 100 parts by weight of the composition of the present invention.

In addition, in the food composition for improving or preventing disease in a disease caused by hyperuricosuria, wherein the overturned hydrolyzate is contained as an effective ingredient, the amount of the overturned hydrolyzate may be 0.00001% to 50% by weight of the total food And in the case of a beverage composition, it is included in a proportion of 0.001 g to 50 g, preferably 0.01 g to 10 g, based on 100 ml of the whole food, but is not limited thereto.

The composition of the present invention is capable of inhibiting xanthine oxidase and is useful for the treatment, improvement or prevention of diseases caused by hyperuricosis including gout, and is manufactured from natural products used for edible purposes, Or a patient at risk of the above-mentioned disease.

The present invention also provides a method for producing an abalone hydrolyzate having an effect of improving or preventing diseases derived from hyperuricemia.

Specifically, the method for producing the overturned hydrolyzate comprises reacting at least one hydrolytic enzyme selected from the group consisting of Alcalase and Neutrase to abalone to produce an abalone built-in enzyme And a hydrolysis step, wherein the enzyme hydrolyzate has an ability to inhibit xanthine oxidase.

Even more remedially, the process for preparing the overturned enzyme hydrolyzate having the ability to inhibit xanthine oxidase comprises a washing step, an internal separation step, a blanching step, a pulverization step, an enzyme hydrolysis step, a filtration step, a concentration step and a drying step And may further include a powder packaging process.

The washing process may be carried out by overturning, for example, by immersing the immersion cloth in a washing tank or running water, and then removing foreign matter on the surface. In view of the efficiency of the processing space, the immersion is preferably carried out in the washing tank.

The built-in separation process may be performed by separating the washed abalone by shell, meat (abalone), or overturned embedding. In order to prevent breakage of the meat or abalone, or quality deterioration, .

In the heating step, in order to inactivate the self-enzyme contained in the separated abalone, the abalone is placed in a large pot at 70 ° C to 120 ° C for 5 minutes to 1 hour, for example at 90 ° C for 15 minutes And then heating it.

The pulverization process may be carried out by using a pulverizer such as a blender for 1 minute to 10 minutes, for example, grinding for 5 minutes.

The enzymatic hydrolysis process can be carried out by sequentially treating the alkalase and the Ntrease in view of the ability of the enzyme to inhibit xanthine oxidase. For example, 5 to 15 times of water or 7 to 12 times of water is added to the overturned pulverized product subjected to the pulverization process in the large-capacity reactor, the alcalase is added, the enzyme reaction is performed , A method in which a Nutraceutical agent is added and an enzymatic reaction is carried out.

For example, the enzymatic digestion process is performed by adding 100 kg of abalone-containing crushed product, adding water (1000 L) 10 times as much as the weight of the abalone crusher, adding 0.3% (300 ml, 720 AU) , Followed by an enzymatic reaction at 60 ± 5 ° C., preferably 60 ± 3 ° C. for 3 hours. Then, Nutraceutical agent was added at a ratio of 0.3% (300 ml, 240 AU) After the enzymatic reaction was carried out at 50 ± 5 ° C., preferably 50 ± 3 ° C. for 3 hours, the temperature was raised to 90 ° C. and heated for 15 minutes to inactivate the alkalase and the Ntrease to terminate the reaction . ≪ / RTI >

The filtration can be performed by filtration of the hydrolyzate obtained by the decomposition of the enzyme to a size of 60 mesh or less or a molecular weight of 10 kDa or less by using a facility such as a basket fitter or a UF-MF system.

The concentration step may be performed by concentrating the filtrate obtained by the filtration step using a concentration apparatus. The drying step may be performed by drying the extraction filtrate using a drier. When pulverization is required, Followed by pulverization using a pulverizer.

The powder packaging process may be performed by a method of packing the powdered hydrolyzate through the drying process using a powder packaging machine.

The fraction of the overturned hydrolyzate produced by the above method is superior to other hydrolysates in the ability to inhibit xanthine oxidase and has an advantage that it can be usefully used in patients having diseases derived from hyperuricemia including gout or in the case of such a danger .

The composition containing the overturned hydrolyzate of the present invention as an active ingredient can inhibit xanthine oxidase and is thus effective for the treatment, prevention or amelioration of diseases derived from hyperuricemia including gout, Treatment, prevention or amelioration of diseases caused by hyperuricemia, including gout with limited development of therapeutic drugs, despite the fact that no side effects are caused by substances derived from natural substances, unlike gout remedies, which do not cause side effects. The present invention proposes a new industrial application using the abalone embankment which has been treated as waste in the abalone processing, which is the object of the active ingredient. Therefore, the income of the abalone industry workers including the abalone farmers and the residents of the fishing villages And contribute to the development of the local economy. In a point it will be a very big impact on the industry.

FIG. 1 shows the results of measuring the inhibitory effect of xanthine oxidase on the abalone hydrolyzate according to the type of the hydrolytic enzyme according to an embodiment of the present invention, wherein the horizontal axis represents the kind of the sample and the vertical axis represents the ratio It shows low performance.
FIG. 2 is a graph showing the inhibition of xanthine oxidase degradation of abalone hydrolyzate according to the treatment time of the hydrolytic enzyme according to an embodiment of the present invention. The abscissa indicates the treatment time (1 hour, 2 hours) of each of alkaline and non- Hour, 3 hours, 4 hours, 5 hours, and 6 hours), and the vertical axis shows a lower performance than the negative control without any sample treatment.
FIG. 3 is a graph showing the results of measuring the inhibitory effect of xanthine oxidase on the abalone hydrolyzate according to the method of treating a hydrolytic enzyme according to an embodiment of the present invention, wherein the abscissa represents the treatment method of alkarase and Nutra, , And the ordinate axis shows a lower performance than that of the negative control without any sample treatment.
FIG. 4 is a schematic view of a method for mass production of an overturned hydrolyzate of the present invention, according to an embodiment of the present invention.

Hereinafter, the present invention will be described in more detail with reference to production examples and examples. However, the following Preparation Examples and Examples are merely illustrative examples for the purpose of facilitating understanding of the present invention, and can be modified into various other forms, and the scope of the present invention is not limited to the following Examples.

[ Example ]

Example  1. Abalone built-in Hydrolyzate  Produce

Freshly abalone ( Haliotis (Nordotis) discus hannai ) of 15 (7 cm to 9 cm) size produced in 2014 in Wando County, Jeollanam-do was purchased and the internal part of abalone was separated and washed.

First, the overturned protein extract used as a control for confirming the effect of the hydrolyzate of abalone was prepared by the following method.

The separated 100 g of the overturned viscera was crushed, 2,000 ml of distilled water was added, and the mixture was extracted at 90 캜 for 3 hours. After the extraction, the filtrate was centrifuged at 6,000 rpm for 30 minutes, and the supernatant was taken to prepare an abalone protein hot-water extract. Protein hydrothermal extracts were stored freeze-dried until used in the experiment.

10 g of the lyophilized hot-water extract was dissolved in 100 mL of distilled water, and the filtrate having a molecular weight of 10 kDa or less was treated first with a 10 kDa UF membrane. And half of them were treated with 5 kDa UF membrane once more to obtain a filtrate of 5 kDa or less. The hollow fiber cartridge (UFP-3-C4A) used for separation according to the molecular weight was purchased from GE Healthcare Bio-Sciences Corp. (USA). The filtrate I having a molecular weight of 5 to 10 kDa and the filtrate II having a molecular weight of 5 kDa or less were concentrated to 10 brix and lyophilized to be used as a sample.

The overturned hydrolyzate as a sample of the present invention was prepared by the following method.

Prior to the production of the abalone hydrolyzate, the autologous enzyme was inactivated to exclude the effect of the self-enzyme contained in the embryo. Specifically, 2,500 mL of distilled water was added to 180 g of the overturned detached and washed detached and washed, followed by blanching at 90 ° C for 15 minutes, followed by cooling at room temperature.

The ontogeny of the inactivated enzyme was hydrolyzed using various proteolytic enzymes. Alkalase, Neutrase, Protamex and Flavourzyme, which are commercial enzymes, were used as the above-mentioned hydrolytic enzymes. Alcalase, Neutrase, Protamex and Flavourzyme were purchased from novozymes (USA).

Specifically, the hydrolyzate was prepared in the following manner.

First, the above-mentioned self-enzymes were deactivated, and then the respective amounts of hydrolytic enzymes corresponding to 0.3% (v / w) of the abalone weight of the abalone were added to the ground abalone, and the hydrolytic enzymes The reaction was allowed to proceed for 3 hours at the optimum temperature and optimum pH, and the enzyme was then deactivated by inactivating the addition enzyme at 90 ° C for 15 minutes. The calorific value of the hydrolytic enzyme contained in 0.54 ml of the hydrolytic enzyme added to each of the above-mentioned abalone 180 g standard was 1.296 AU in the case of Alcalase, 0.432 AU in the case of Neutrase, 0.81 AU for Protamex and 270 LAPU for Flavourzyme.

Enzyme name Optimum temperature (℃) Optimum pH Alcalase 60 6.5 to 8.5 Neutrase 45 to 55 5.5 to 7.5 Protamex 35 to 60 5.5 to 7.5 Flavourzyme 50 5.0 to 7.0

After the enzyme reaction was terminated, the enzyme hydrolyzate was filtered under reduced pressure using a filter paper (Watman No. 2), and the filtrate was centrifuged at 6,000 rpm for 30 minutes. Then, the supernatant was taken to prepare the abalone hydrolyzate , And the overturned hydrolyzate was stored by freeze drying until used in the experiment.

In order to separate the overturned hydrolyzate according to its molecular weight, 10 g of the lyophilized overturned hydrolyzate was dissolved in 100 mL of distilled water and treated with a 10 kDa UF membrane to give a molecular weight of 10 kDa, and half of the filtrate was treated with 5 kDa UF membrane once more to obtain a filtrate of 5 kDa or less. The filtrate I having a molecular weight of 5 to 10 kDa and the filtrate II having a molecular weight of 5 kDa or less were concentrated to 10 brix and lyophilized to be used as a sample.

The obtained abalone inner hydrolyzate and abalone inner extract were stored in a deep freezer until use, and the hydrolyzate and extracts thus prepared were named as shown in Table 2 below.

Manufacturing method Molecular Weight Name of sample Hot water extraction 5 kDa or less (II) HW5 5 to 10 kDa (I) HW10 Enzymatic degradation Alcalase 5 kDa or less (II) AL5 5 to 10 kDa (I) AL10 Neutrase 5 kDa or less (II) NE5 5 to 10 kDa (I) NE10 Protamex 5 kDa or less (II) PR5 5 to 10 kDa (I) PR10 Flavourzyme 5 kDa or less (II) FL5 5 to 10 kDa (I) FL10

Example  2. Built-in abalone Hydrolyzate Xanthine  Identification of the inhibitory effect of oxydase (1)

The anticorrosive activity of the invertible hydrolyzate prepared in Example 1 and the control hydrolyzate of Jeonbuk proved to be inferior to xanthine oxidase (XO). The ACE inhibitory activity was measured by adding xanthine oxidase (from bovine milk) (Sigma, USA) and xanthine oxidase (Sigma, USA) using xanthine , And the amount of uric acid produced was compared with that of the control group. The specific measurement method is as follows.

First, 100 μL of the sample solution of Table 2 prepared in Example 1 at a concentration of 100 μg / mL and 200 μL of a 1 mM xanthine solution were mixed in 0.6 mL of 0.1 M potassium phosphate buffer (pH 7.5), followed by the addition of xanthine oxidase (0.2 unit / mL) were mixed and reacted at 37 ° C for 5 minutes. After the reaction, 200 μL of 1N HCl was added to stop the reaction, and the protein was removed by centrifugation at 12,000 rpm for 10 minutes.

From the solution from which the protein was removed, the resultant uric acid produced from the xanthine was measured at 292 nm, and the resultant was added to the previously prepared calibration curve to compare the inhibitory effect of each sample on the uric acid production. The measurement results are shown in Fig.

As shown in Fig. 1, all of hydrolysates hydrolyzed by using Protamex (PR) and Flavourzyme (FL) as well as overturned hot water extract (HW) showed no inhibitory effect on uric acid production, that is, no effect of xanthine oxidase inhibition On the other hand, the hydrolyzate hydrolyzed with Alcalase (AL) and Neutrase (NE) showed a slight difference in activity depending on the molecular weight, but it can inhibit xanthine production by inhibiting xanthine oxidase significantly , And it was confirmed that the effect of inhibiting uric acid production was better when using the alkalase.

Example  3. Built-in abalone Hydrolyzate Xanthine  Identification of the inhibitory effect of oxydase (2)

The effect of the treatment time and the treatment method was confirmed in order to confirm the hydrolysis method of the hydrolyzate using the alkarase and the Ntrans agent which had been confirmed to have the ability to inhibit the xanthine oxidase in Example 2.

First, the hydrolysis reaction was carried out in the same manner as in Example 1 except that the hydrolysis reaction was carried out at different treatment times, and the molecular size of the enzyme degraded by the enzyme was affected by the inhibitory effect of xanthine oxidase Since it was confirmed to be insignificant, no separate separation for molecular weight classification was performed.

The inhibition of xanthine oxidase of the hydrolyzate prepared according to each of the above reaction times was measured in the same manner as in Example 2 above. The measurement results are shown in Fig.

As shown in FIG. 2, when the enzymatic hydrolyzate of the enzyme hydrolyzate was reacted with xanthine, the inhibitory activity of xanthine was increased up to 3 hours in the case of alkarase, , And it was confirmed that the hydrolysis reaction was abruptly lowered after 6 hours of operation. In the case of Ntrease, the maximum inhibitory activity increased from 3 hours after the reaction to 4 hours, and then decreased from 5 hours after the reaction , It was confirmed that the optimum reaction time of the hydrolytic enzyme was 3 hours to 5 hours. The optimum reaction time was found to be 3 hours in the case of alkarase and 4 hours in case of Ntrease by each reaction enzyme.

The hydrolysis reaction was carried out in the same manner as in Example 1 except that the amount of the hydrolytic enzyme to be treated and the treatment method were changed, Since the molecular size of the degradation product was confirmed to have no effect on the inhibition of xanthine oxidase, no separate separation was performed for molecular weight classification.

Specifically, the protein-derived substance having the ability to inhibit xanthine oxidase from abalone, that is, the hydrolytic enzyme capable of producing the polypeptide, is mixed with the alcalase of Example 1 and the Ntrease in a volume ratio of 2: 1, 1: 1, 3: 1 and 3: 2 on the basis of the content (AU) of 1: 1 and 1: 2, and the hydrolytic enzyme had a total treatment content of 0.3% (v / w) ), And in the case of the treatment method, the simultaneous treatment method of simultaneously treating the alkalase and the Ntrease, or the reaction of the alkarase at the temperature of 57 to 63 ° C for 3 hours, Was reacted for 3 hours.

The inhibition of xanthine oxidase of the hydrolyzate prepared according to each mixing treatment ratio and treatment method was measured in the same manner as in Example 3 above. The measurement results are shown in Fig.

As shown in Fig. 3, when xanthine oxidase inhibition activity of the invertible hydrolysates according to the mixed treatment ratio and the mixed treatment method of the alcalase and the ntrast agent was compared, it was found that the ratio of the alkarase and the nitrogen The inhibition activity of the sample treated with the 2: 1 ratio of alcalase and Ntrastase was highest at 48.21 ± 1.26, and the ratio of 1: 1 The inhibition activity of the sample treated with the ratio of 1: 2 of alcalase and Ntrastase was found to be the lowest of 24.31 ± 2.33, and the optimal treatment with alcalase and Ntrease The ratio was found to be 2: 1. In addition, in relation to the treatment method, an alkalase whose reaction optimum time was shorter than that of Nutra by 3 hours was added at the beginning of the enzyme reaction and reacted for 3 hours, followed by the addition of Nutraceuticals for 3 hours It was confirmed that the sequential treatment method in which the reaction was carried out was more excellent. Specifically, the inhibitory activity of the samples treated with the 2: 1 ratio of alkarase and Ntrease was 63.43 ± 2.22, which was the highest in all samples, and the ratio of 1: 1 (41.26 ± 3.56) and 1: 2 (31.30 ± 2.02), the excellent effect of about 7% to 15% or more was confirmed in comparison with the simultaneous treatment method.

According to the above results, the optimal conditions for the production of the invertible hydrolysates for the treatment of diseases caused by hyperuricemia and arteriosclerosis, such as gout, are as follows: firstly, the alkalase is first treated at the optimum reaction conditions with the alkalase and the Ntrease, Followed by sequential treatment at a later time and a treatment capacity ratio of 2: 1 (Alcalase: Nutraceutical).

Example  4. Built-in abalone Hydrolyzate  Mass production method

In order to industrially utilize the overturned hydrolyzate of the present invention produced according to the optimum processing conditions as confirmed in Examples 2 and 3, a mass production method was examined. In the optimization process, the method shown in FIG. 4 was selected Specific methods are described below.

The mass production method includes a washing process, a visceral separation process, a blanching process, a pulverizing process, an enzymatic hydrolysis process, a filtration process, a concentration process, a drying and crushing process, and a powder packing process.

The washing process may be carried out by overturning, for example, by immersing the immersion cloth in a washing tank or running water, and then removing foreign matter on the surface. In view of the efficiency of the processing space, the immersion is preferably carried out in the washing tank.

The built-in separation process may be performed by separating the washed abalone by shell, meat (abalone), or overturned embedding. In order to prevent breakage of the meat or abalone, or quality deterioration, .

In the heating step, in order to inactivate the self-enzyme contained in the separated abalone, the abalone is placed in a large pot at 70 ° C to 120 ° C for 5 minutes to 1 hour, for example at 90 ° C for 15 minutes And then heating it.

The pulverization process may be carried out by using a pulverizer such as a blender for 1 minute to 10 minutes, for example, grinding for 5 minutes.

The enzymatic hydrolysis process can be carried out by sequentially treating the alkalase and the Ntrease in view of the ability of the enzyme to inhibit xanthine oxidase. For example, 300 kg of the abrasive agglomerates having been subjected to the above-mentioned pulverization process was added to a large-capacity reactor, and then water (3000 L) was added 10 times as much as the weight, and the alcalase was added in an amount of 0.3% And then the enzyme reaction was carried out at 60 ± 5 ° C., preferably 60 ± 3 ° C. for 3 hours. Then, Nutraceutical was added at a ratio of 0.3% (900 ml) Deg.] C, preferably 50 [deg.] C to 3 [deg.] C for 3 hours, heating the reaction mixture to 90 [deg.] C and heating for 15 minutes to inactivate the alcalase and the Ntrease Respectively.

The filtration process may be performed by filtrating the hydrolyzate to a size of 60 mesh or less or a molecular weight of 10 kDa or less by using a facility such as a basket fitter or a UF-MF system.

The concentration step may be performed by concentrating the filtrate obtained by the filtration step using a concentration apparatus. In the drying and crushing step, the extraction filtrate is dried using a drier. When the pulverization is necessary, And the like.

The powder packaging process may be performed by a method of packing the powdered hydrolyzate through the drying process using a powder packaging machine.

[ Manufacturing example ] Abalone built-in The hydrolyzate  Used formulation

Manufacturing example  One. Sanje  Produce

Abalone hydrolyzate powder 20 mg

Lactose 100 mg

Talc 10 mg

The above ingredients were mixed and filled in an airtight container to prepare powders.

Manufacturing example  2. Preparation of tablets

Abalone hydrolyzate powder 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets were prepared by tableting according to the usual preparation method of tablets.

Manufacturing example  3. Preparation of capsules

Abalone hydrolyzate powder 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components were mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Manufacturing example  4. Liquid  Produce

Abalone hydrolyzate powder 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

Manufacturing example  5. Manufacture of health food

1000 mg of abalone hydrolyzate powder

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg vitamin B1

0.15 mg of vitamin B2

0.5 mg vitamin B6

0.2 [mu] g vitamin B12

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

Claims (7)

A composition for inhibiting xanthine oxidase comprising, as an active ingredient, an abalone built-in hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase. Low back pain, hyperlipemia, hyperuricemia, and uricosuria, which include an abalone hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase. Wherein the composition is selected from the group consisting of: 3. The method of claim 2,
The overturned hydrolyzate of the present invention can be obtained by treating the abalone with a treatment amount of Alcalase and Neutrase at a ratio of 6: 1 (Alkalase: Nutraceutical) based on the enzyme activity unit, Wherein the composition is a food composition for improving or preventing a disease caused by hyperuricosidic disease. 3. The method of claim 2,
The overturned hydrolyzate of claim 1, wherein the overturned hydrolyzate is obtained by treating the overturned embankment sequentially with Alcalase, then treating it with Neutrase, and hydrolyzing the resultant to obtain a composition for improving or preventing hyperuricosidic disease . 3. The method of claim 2,
Characterized in that the overturned hydrolyzate is obtained by hydrolyzing the abalone with one or more hydrolases selected from the group consisting of Alcalase and Neutrase for 3 hours to 5 hours. A food composition for improving or preventing a disease caused by a disease. 3. The method of claim 2,
Wherein the disease caused by hyperuricemia is gout. Low back pain, hyperlipemia, hyperuricemia, and uricosuria, which include an abalone hydrolyzate hydrolyzed by using at least one hydrolase selected from the group consisting of Alcalase and Neutrase. Wherein the composition is used for treating or preventing any disease caused by hyperuricosuria.

Images